Technical Analysis for GMAB - Genmab A/S

Grade Last Price % Change Price Change
grade A 20.36 0.89% 0.18
GMAB closed up 0.89 percent on Wednesday, August 21, 2019, on 46 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical GMAB trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Narrow Range Bar Range Contraction 0.89%
Wide Bands Range Expansion 0.89%
Overbought Stochastic Strength 0.89%
Narrow Range Bar Range Contraction 0.10%
NR7 Range Contraction 0.10%
Wide Bands Range Expansion 0.10%
Overbought Stochastic Strength 0.10%

Older signals for GMAB ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Medicine Biotechnology Cancer Clinical Medicine Drugs Immunology Treatment Of Cancer Solid Tumors Antibodies Monoclonal Antibodies Multiple Sclerosis Non Small Cell Lung Cancer Lymphoma Parkinson's Disease Acute Myeloid Leukemia Multiple Myeloma Immunotherapies Chronic Lymphocytic Leukemia Antibody Drug Conjugates Seattle Genetics Orphan Drugs Breakthrough Therapy Camidanlumab Tesirine Treatment Of Chronic Lymphocytic Leukemia Advanced Cancers Amyloidosis
Is GMAB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.45
52 Week Low 1.1
Average Volume 318,910
200-Day Moving Average 2.725
50-Day Moving Average 6.6388
20-Day Moving Average 14.7835
10-Day Moving Average 19.819
Average True Range 0.8475
ADX 69.4
+DI 70.3532
-DI 2.3783
Chandelier Exit (Long, 3 ATRs ) 18.9075
Chandelier Exit (Short, 3 ATRs ) 3.6725
Upper Bollinger Band 30.5894
Lower Bollinger Band -1.0224
Percent B (%b) 0.68
BandWidth 213.831637
MACD Line 4.5243
MACD Signal Line 4.5022
MACD Histogram 0.0221
Fundamentals Value
Market Cap 1.93 Billion
Num Shares 94.7 Million
EPS -1.91
Price-to-Earnings (P/E) Ratio -10.66
Price-to-Sales 0.02
Price-to-Book 0.00
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.69
Resistance 3 (R3) 20.69 20.59 20.64
Resistance 2 (R2) 20.59 20.50 20.59 20.62
Resistance 1 (R1) 20.47 20.45 20.42 20.47 20.60
Pivot Point 20.37 20.37 20.34 20.37 20.37
Support 1 (S1) 20.25 20.28 20.20 20.25 20.12
Support 2 (S2) 20.15 20.23 20.15 20.10
Support 3 (S3) 20.03 20.15 20.09
Support 4 (S4) 20.03